Use of classic psychedelics may lower a person’s odds of developing opioid use disorder, said a new study published in the journal Scientific Reports.
Pear Therapeutics, Inc. has announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options.
The pandemic has undoubtedly altered the way of life for all Americans, but it has also shed light into the bleak statistics that are showing the opioid crisis is even worse than ever before. For the first time in history, the Centers for Disease Control and Prevention (CDC) reported that nearly 100,000 Americans died from drug overdoses over a 12-month period ending in March 2021, which was a little more than a 30 percent increase from the previous year.
Indivior’s experimental drug to help fight America’s growing opioid addiction crisis was approved by the U.S. Food and Drug Administration, boosting the company’s sales prospects as competitors threaten revenues from an older product.
Indivior PLC announced that the U.S. FDA approved Sublocade (buprenorphine extended-release) injection for subcutaneous use (CIII), the first and only once-monthly injectable buprenorphine formulation for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by dose adjustment for a minimum of seven days.
The U.S. FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18-to-1 to recommend Indivior’s RBP-6000 to treat opioid use disorder.